Sun has inked another commercial partnership to bring psoriasis drug Ilumya to countries outside India, this time teaming with Hikma in the MENA region.
Sun Pharmaceutical Industries continues to strike deals to expand market access and availability of its lead psoriasis asset Ilumya (tildrakizumab). India’s top-ranked biopharma sealed an exclusive licensing and distribution agreement on 15 June for Ilumya with Hikma Pharmaceuticals for the Middle East and North Africa (MENA) region.
Under the deal terms, Hikma will handle the registration and commercialization of the product in all MENA markets, while Sun...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
